India’s weight-loss drug sales lose momentum in August
- India’s weight-loss drug market stabilises in August after a sharp surge following generic semaglutide’s entry.
- GLP-1 sales rise marginally to ₹247 crore in August from ₹245 crore in July, showing slower growth.
- Injectable semaglutide sales increase to ₹76 crore, while oral formulations see a slight decline during the month.
- Despite 33 generic injectable brands, 11 brands account for 80% of unit sales, while Mounjaro leads the market.
Source: financialexpress.com
Get 100 stories a day on the app
Read, watch & listen · Free on iOS & Android
